Australia expects to receive AstraZeneca's COVID-19 vaccine within months

Australia expects to receive AstraZeneca's COVID-19 vaccine within months

AstraZeneca has established a separate commercial arrangement with the Australian government to supply its COVID-19 vaccine candidate to Australia after successful completion of clinical trials.

"This is one of the world's most prospective vaccines and one of the world's most advanced vaccines", the Minister said.

Participants in the phase three trial will be randomly chosen to receive a dose of the potential vaccine or the placebo, details of the trial reports, which will help determine whether the vaccine is safe and effective, researches will follow the participants for more than two years.

Should both vaccines pass clinical trials, Australia will spend A$1.7 billion ($1.24 billion) for a total of almost 85 million doses, Morrison said.

Medical journal The Lancet's chief editor has said that US President Donald Trump's statement that a Covid-19 vaccine could be delivered by the end of October is "simply wrong".

Johnson & Johnson has reported a second successful animal trial of Ad26.COV2.S (adenovirus serotype 26), its single-dose candidate COVID-19 vaccine now under development as part of Operation Warp Speed (OWS).

"Nagbigay sila ng information na hindi sila gagawa ng clinical trial sa Philippines because they are well advanced already with their Phase 3 clinical trials". UNICEF will also coordinate the procurement of the Coronavirus vaccine by about 80 higher income countries who have evinced interest to participate in the Covax facility by financing vaccines for low-income countries by their own budgets.

Currently, the University of Queensland is performing Phase 1 clinical trial of UQCSL V451 to assess the safety as well as immunogenicity in healthy subjects.

She said they will also finalize a confidentiality disclosure agreement or CDA with the vaccine maker.

Unexpectedly, last Thursday, the US Centers for Disease Control and Prevention announced that it had sent letters to governors of all 50 American states to prepare for a COVID-19 vaccine to be ready for distribution by November 1. The vaccine candidate AZD1222 requires a two-dose/person regime.

However the positive results in hamsters by no means guarantee the effectiveness of the vaccine in humans.

"CSL's history is linked with a commitment to Australia's public health needs".

Related Articles